MedTrace Logo

Safety and Efficacy Study of LHW090 in Resistant Hypertension Patients

NCT02515331 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2021-01-05

Study results available
· View outcomes & findings →

Summary

The purpose of the present study was to determine whether LHW090 displays the clinical safety and efficacy profile to support further development in patients with resistant hypertension.

Conditions

  • Patients, Resistant Hypertension

Interventions

DRUG

LHW090

Capsule - oral dose

DRUG

Placebo

Capsule - oral dose

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-04
Primary Completion
2017-08-17
Completion
2017-08-17

Countries

  • United States
  • Denmark
  • France
  • Germany
  • Netherlands
  • Switzerland

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02515331 on ClinicalTrials.gov